238 related articles for article (PubMed ID: 32466123)
1. Pipeline for the Generation and Characterization of Transgenic Human Pluripotent Stem Cells Using the CRISPR/Cas9 Technology.
Mianné J; Bourguignon C; Nguyen Van C; Fieldès M; Nasri A; Assou S; De Vos J
Cells; 2020 May; 9(5):. PubMed ID: 32466123
[TBL] [Abstract][Full Text] [Related]
2. Efficient CRISPR-Cas9-mediated generation of knockin human pluripotent stem cells lacking undesired mutations at the targeted locus.
Merkle FT; Neuhausser WM; Santos D; Valen E; Gagnon JA; Maas K; Sandoe J; Schier AF; Eggan K
Cell Rep; 2015 May; 11(6):875-883. PubMed ID: 25937281
[TBL] [Abstract][Full Text] [Related]
3. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.
Ihry RJ; Worringer KA; Salick MR; Frias E; Ho D; Theriault K; Kommineni S; Chen J; Sondey M; Ye C; Randhawa R; Kulkarni T; Yang Z; McAllister G; Russ C; Reece-Hoyes J; Forrester W; Hoffman GR; Dolmetsch R; Kaykas A
Nat Med; 2018 Jul; 24(7):939-946. PubMed ID: 29892062
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-based Targeted Genome Editing for the Development of Monogenic Diseases Models with Human Pluripotent Stem Cells.
Gupta N; Susa K; Yoda Y; Bonventre JV; Valerius MT; Morizane R
Curr Protoc Stem Cell Biol; 2018 May; 45(1):e50. PubMed ID: 30040245
[TBL] [Abstract][Full Text] [Related]
5. A Scaled Framework for CRISPR Editing of Human Pluripotent Stem Cells to Study Psychiatric Disease.
Hazelbaker DZ; Beccard A; Bara AM; Dabkowski N; Messana A; Mazzucato P; Lam D; Manning D; Eggan K; Barrett LE
Stem Cell Reports; 2017 Oct; 9(4):1315-1327. PubMed ID: 29020615
[TBL] [Abstract][Full Text] [Related]
6. Semi-automated optimized method to isolate CRISPR/Cas9 edited human pluripotent stem cell clones.
Frank E; Cailleret M; Nelep C; Fragner P; Polentes J; Herardot E; El Kassar L; Giraud-Triboult K; Monville C; Ben M'Barek K
Stem Cell Res Ther; 2023 Apr; 14(1):110. PubMed ID: 37106426
[TBL] [Abstract][Full Text] [Related]
7. Generation of Defined Genomic Modifications Using CRISPR-CAS9 in Human Pluripotent Stem Cells.
Cardenas-Diaz FL; Maguire JA; Gadue P; French DL
J Vis Exp; 2019 Sep; (151):. PubMed ID: 31609348
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Protocols for CRISPR/Cas9-based Gene Editing in Human Pluripotent Stem Cells.
Santos DP; Kiskinis E; Eggan K; Merkle FT
Curr Protoc Stem Cell Biol; 2016 Aug; 38():5B.6.1-5B.6.60. PubMed ID: 27532820
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 genome editing in human pluripotent stem cells: Harnessing human genetics in a dish.
González F
Dev Dyn; 2016 Jul; 245(7):788-806. PubMed ID: 27145095
[TBL] [Abstract][Full Text] [Related]
10. An episomal vector-based CRISPR/Cas9 system for highly efficient gene knockout in human pluripotent stem cells.
Xie Y; Wang D; Lan F; Wei G; Ni T; Chai R; Liu D; Hu S; Li M; Li D; Wang H; Wang Y
Sci Rep; 2017 May; 7(1):2320. PubMed ID: 28539611
[TBL] [Abstract][Full Text] [Related]
11. Precise and efficient scarless genome editing in stem cells using CORRECT.
Kwart D; Paquet D; Teo S; Tessier-Lavigne M
Nat Protoc; 2017 Feb; 12(2):329-354. PubMed ID: 28102837
[TBL] [Abstract][Full Text] [Related]
12. Highly Efficient CRISPR-Cas9-Mediated Genome Editing in Human Pluripotent Stem Cells.
Maguire JA; Cardenas-Diaz FL; Gadue P; French DL
Curr Protoc Stem Cell Biol; 2019 Feb; 48(1):e64. PubMed ID: 30358158
[TBL] [Abstract][Full Text] [Related]
13. Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-Associated Endonuclease Cas9-Mediated Homology-Independent Integration for Generating Quality Control Materials for Clinical Molecular Genetic Testing.
Lin G; Zhang K; Peng R; Han Y; Xie J; Li J
J Mol Diagn; 2018 May; 20(3):373-380. PubMed ID: 29680088
[TBL] [Abstract][Full Text] [Related]
14. Developing CRISPR/Cas9-Mediated Fluorescent Reporter Human Pluripotent Stem-Cell Lines for High-Content Screening.
Vojnits K; Nakanishi M; Porras D; Kim Y; Feng Z; Golubeva D; Bhatia M
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458632
[TBL] [Abstract][Full Text] [Related]
15. Highly Efficient CRISPR/Cas9-Mediated Genome Editing in Human Pluripotent Stem Cells.
Maguire JA; Gadue P; French DL
Curr Protoc; 2022 Nov; 2(11):e590. PubMed ID: 36426905
[TBL] [Abstract][Full Text] [Related]
16. Production of genome-edited pluripotent stem cells and mice by CRISPR/Cas.
Horii T; Hatada I
Endocr J; 2016; 63(3):213-9. PubMed ID: 26743444
[TBL] [Abstract][Full Text] [Related]
17. Conditional Gene Knockout in Human Cells with Inducible CRISPR/Cas9.
Snijders KE; Cooper JD; Vallier L; Bertero A
Methods Mol Biol; 2019; 1961():185-209. PubMed ID: 30912047
[TBL] [Abstract][Full Text] [Related]
18. Introducing Large Genomic Deletions in Human Pluripotent Stem Cells Using CRISPR-Cas3.
Hou Z; Hu C; Ke A; Zhang Y
Curr Protoc; 2022 Feb; 2(2):e361. PubMed ID: 35129865
[TBL] [Abstract][Full Text] [Related]
19. Efficient CRISPR/Cas9-Based Genome Engineering in Human Pluripotent Stem Cells.
Kime C; Mandegar MA; Srivastava D; Yamanaka S; Conklin BR; Rand TA
Curr Protoc Hum Genet; 2016 Jan; 88():21.4.1-21.4.23. PubMed ID: 26724721
[TBL] [Abstract][Full Text] [Related]
20. Generating CRISPR-Cas9-Mediated Null Mutations and Screening Targeting Efficiency in Human Pluripotent Stem Cells.
Bower OJ; McCarthy A; Lea RA; Alanis-Lobato G; Zohren J; Gerri C; Turner JMA; Niakan KK
Curr Protoc; 2021 Aug; 1(8):e232. PubMed ID: 34432381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
